Dublin, Jan. 02, 2018 (GLOBE NEWSWIRE) -- The "H3N2 Infection - Pipeline Insights, 2017" drug pipelines has been added to Research and Markets' offering.
H3N2 Infection-Pipeline Insights, 2017 provides comprehensive insights of the ongoing therapeutic research and development across H3N2 Infection. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of H3N2 Infection by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.
Scope of the Report:
- The report provides a snapshot of the pipeline development for the H3N2 Infection
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the H3N2 Infection
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for H3N2 Infection
- The report also covers the dormant and discontinued pipeline projects related to the H3N2 Infection
Reasons to Buy:
- Establish comprehensive understanding of the pipeline activity across this H3N2 Infection to formulate effective R&D strategies
- Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of H3N2 Infection therapeutics
- Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
Key Topics Covered:
1. Report Introduction
2. H3N2 Infection Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for H3N2 Infection
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Companies Mentioned
- AIMM Therapeutics BV
- Aphios Corp
- BiondVax Pharmaceuticals Ltd
- Celltrion Inc
- FluGen Inc
- Glide Pharmaceutical Technologies Ltd
- ILiAD Biotechnologies LLC
- Inovio Pharmaceuticals Inc
- Johnson & Johnson
- Medicago Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vk7pgw/global_h3n2?w=12
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs